Medifast (NYSE:MED) Issues Q1 2025 Earnings Guidance

Medifast (NYSE:MED) updated its first quarter 2025 earnings guidance on Tuesday. The company provided earnings per share guidance of -0.500-0.000 for the period, compared to the consensus earnings per share estimate of -0.190. The company issued revenue guidance of $100.0 million-$120.0 million, compared to the consensus revenue estimate of $130.8 million.

Wall Street Analysts Forecast Growth

Separately, DA Davidson upgraded shares of Medifast from an “underperform” rating to a “neutral” rating and boosted their price objective for the stock from $16.50 to $17.00 in a report on Tuesday, November 5th.

Medifast Stock Down 1.0 %

NYSE MED traded down $0.16 during mid-day trading on Tuesday, reaching $16.05. 280,528 shares of the company’s stock traded hands, compared to its average volume of 212,304. The company has a current ratio of 3.11, a quick ratio of 2.55 and a debt-to-equity ratio of 0.06. The company has a market cap of $175.55 million, a price-to-earnings ratio of 24.32 and a beta of 1.14. Medifast has a 1-year low of $14.76 and a 1-year high of $49.90. The company has a fifty day simple moving average of $16.61 and a 200-day simple moving average of $18.05.

Medifast (NYSE:MED) last issued its earnings results on Tuesday, February 18th. The specialty retailer reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.16) by $0.26. Medifast had a return on equity of 15.98% and a net margin of 1.09%. As a group, equities research analysts expect that Medifast will post 1.68 EPS for the current year.

Medifast Company Profile

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.